Please wait while the formulary information is being retrieved.
Drug overview for ORSERDU (elacestrant hcl):
Generic name: elacestrant HCl (EL-a-KES-trant)
Drug class: Antiestrogen
Therapeutic class: Antineoplastics
Elacestrant hydrochloride, an estrogen receptor antagonist, is an antineoplastic agent.
No enhanced Uses information available for this drug.
Generic name: elacestrant HCl (EL-a-KES-trant)
Drug class: Antiestrogen
Therapeutic class: Antineoplastics
Elacestrant hydrochloride, an estrogen receptor antagonist, is an antineoplastic agent.
No enhanced Uses information available for this drug.
DRUG IMAGES
ORSERDU 86 MG TABLET
The following indications for ORSERDU (elacestrant hcl) have been approved by the FDA:
Indications:
ER-positive, HER2-negative, ESR1-mutated breast cancer
Professional Synonyms:
None.
Indications:
ER-positive, HER2-negative, ESR1-mutated breast cancer
Professional Synonyms:
None.
The following dosing information is available for ORSERDU (elacestrant hcl):
Dosage of elacestrant hydrochloride is expressed in terms of elacestrant.
If adverse reactions occur during elacestrant therapy, temporary interruption, dosage reduction, and/or permanent discontinuance of the drug may be necessary. If dosage modification is required, reduce the dosage of elacestrant as described below (see Table 1).
Table 1. Recommended Dosage Reduction for Elacestrant Toxicity.
Dosage Reduction Level Recommended Dosage First dose reduction 258 mg (three 86 mg tablets) orally once daily Second dose reduction 172 mg (two 86 mg tablets) orally once daily
Permanently discontinue elacestrant if further dose reduction below 172 mg is required.
Recommended dosage modifications for adverse reactions based on severity are listed below (see Table 2).
Table 2. Recommended Dosage Modifications for Elacestrant Adverse Reactions.
Severity Recommendation Grade 1 Continue at current dosage level. Grade 2 Consider interruption until recovery to grade 1 or less or baseline, then resume at the same dosage level Grade 3 Interrupt therapy until recovery to grade 1 or less or baseline, then resume at the next lower dosage level If grade 3 toxicity recurs, interrupt therapy until recovery to grade 1 or less or baseline, then resume therapy reduced by another dosage level Grade 4 Interrupt therapy until recovery to grade 1 or less or baseline, then resume therapy reduced by 1 dosage level. If grade 4 or intolerable adverse reaction recurs, permanently discontinue elacestrant.
If adverse reactions occur during elacestrant therapy, temporary interruption, dosage reduction, and/or permanent discontinuance of the drug may be necessary. If dosage modification is required, reduce the dosage of elacestrant as described below (see Table 1).
Table 1. Recommended Dosage Reduction for Elacestrant Toxicity.
Dosage Reduction Level Recommended Dosage First dose reduction 258 mg (three 86 mg tablets) orally once daily Second dose reduction 172 mg (two 86 mg tablets) orally once daily
Permanently discontinue elacestrant if further dose reduction below 172 mg is required.
Recommended dosage modifications for adverse reactions based on severity are listed below (see Table 2).
Table 2. Recommended Dosage Modifications for Elacestrant Adverse Reactions.
Severity Recommendation Grade 1 Continue at current dosage level. Grade 2 Consider interruption until recovery to grade 1 or less or baseline, then resume at the same dosage level Grade 3 Interrupt therapy until recovery to grade 1 or less or baseline, then resume at the next lower dosage level If grade 3 toxicity recurs, interrupt therapy until recovery to grade 1 or less or baseline, then resume therapy reduced by another dosage level Grade 4 Interrupt therapy until recovery to grade 1 or less or baseline, then resume therapy reduced by 1 dosage level. If grade 4 or intolerable adverse reaction recurs, permanently discontinue elacestrant.
Administer orally once daily at approximately the same time each day. Administer elacestrant with food to reduce nausea and vomiting. Swallow tablets whole; do not chew, crush, or split prior to swallowing.
Do not take any tablets that are broken, cracked, or look damaged. If a dose is missed for >6 hours or vomiting occurs, skip the dose and take the next dose on the following day at its regularly scheduled time. Store tablets at 20-25degreesC (excursions permitted between 15-30degreesC).
Do not take any tablets that are broken, cracked, or look damaged. If a dose is missed for >6 hours or vomiting occurs, skip the dose and take the next dose on the following day at its regularly scheduled time. Store tablets at 20-25degreesC (excursions permitted between 15-30degreesC).
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| ORSERDU 86 MG TABLET | Maintenance | Adults take 3 tablets (258 mg) by oral route once daily |
| ORSERDU 345 MG TABLET | Maintenance | Adults take 1 tablet (345 mg) by oral route once daily |
No generic dosing information available.
The following drug interaction information is available for ORSERDU (elacestrant hcl):
There are 3 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Elacestrant/Strong and Moderate CYP3A4 Inducers SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Elacestrant is metabolized by CYP3A4. Strong and moderate inducers of CYP3A4 may increase the metabolism of elacestrant.(1) CLINICAL EFFECTS: Concurrent use of a strong or moderate inducer of CYP3A4 may result in decreased levels and effectiveness of elacestrant.(1) PREDISPOSING FACTORS: Induction effects may be more likely with regular use of the inducer for longer than 1-2 weeks. PATIENT MANAGEMENT: The US manufacturer of elacestrant states avoid concomitant use of elacestrant with strong or moderate CYP3A4 inducers.(1) The US manufacturer of elacestrant does not provide dose modification recommendations with strong and moderate CYP3A4 inducers. The Australian and UK manufacturers of elacestrant state concomitant use of strong or moderate CYP3A4 inducers should be avoided and an alternative concomitant medicinal product with no or minimal potential to induce CYP3A4 should be considered. If a strong or moderate CYP3A4 inducer must be used for a short duration of time (i.e. less than or equal to 3 days) or intermittently (i.e. treatment periods less than or equal to 3 days separated by at least 2 weeks or 1 week + 5 half-lives of the CYP3A4 inducer, whichever is longer), continue elacestrant without increasing the dose.(2,3) DISCUSSION: Coadministration of 200 mg dose of elacestrant with rifampin (a strong CYP3A inducer) decreased the maximum concentration (Cmax) and area-under-curve (AUC) of elacestrant by 73% and 86%, respectively.(1) Efavirenz is predicted to decrease the Cmax and AUC of elacestrant by 44 to 63% and 55% to 73%, respectively.(1) Strong inducers of CYP3A4 include: apalutamide, barbiturates, carbamazepine, encorafenib, enzalutamide, fosphenytoin, ivosidenib, lumacaftor, mitotane, phenobarbital, phenytoin, primidone, rifampin, rifapentine, and St. John's wort.(4,5) Moderate inducers of CYP3A4 include: belzutifan, bosentan, cenobamate, dabrafenib, dipyrone, efavirenz, elagolix, etravirine, fexinidazole, lesinurad, lorlatinib, mavacamten, mitapivat, modafinil, nafcillin, pacritinib, pexidartinib, repotrectinib, rifabutin, sotorasib, telotristat, thioridazine, and tovorafenib.(4,5) |
AQVESME, ASA-BUTALB-CAFFEINE-CODEINE, ASCOMP WITH CODEINE, AUGTYRO, BOSENTAN, BRAFTOVI, BUTALB-ACETAMINOPH-CAFF-CODEIN, BUTALBITAL, BUTALBITAL-ACETAMINOPHEN, BUTALBITAL-ACETAMINOPHEN-CAFFE, BUTALBITAL-ASPIRIN-CAFFEINE, CAMZYOS, CARBAMAZEPINE, CARBAMAZEPINE ER, CARBATROL, CEREBYX, DILANTIN, DILANTIN-125, DONNATAL, EFAVIRENZ, EFAVIRENZ-EMTRIC-TENOFOV DISOP, EFAVIRENZ-LAMIVU-TENOFOV DISOP, EQUETRO, ERLEADA, ETRAVIRINE, FIORICET, FOSPHENYTOIN SODIUM, INTELENCE, LORBRENA, LUMAKRAS, LYSODREN, MITOTANE, MODAFINIL, MYSOLINE, NAFCILLIN, NAFCILLIN SODIUM, OJEMDA, ORIAHNN, ORILISSA, ORKAMBI, PENTOBARBITAL SODIUM, PHENOBARBITAL, PHENOBARBITAL SODIUM, PHENOBARBITAL-BELLADONNA, PHENOBARBITAL-HYOSC-ATROP-SCOP, PHENOHYTRO, PHENYTEK, PHENYTOIN, PHENYTOIN SODIUM, PHENYTOIN SODIUM EXTENDED, PRIFTIN, PRIMIDONE, PROVIGIL, PYRUKYND, RIFABUTIN, RIFADIN, RIFAMPIN, SEZABY, SYMFI, TAFINLAR, TALICIA, TEGRETOL, TEGRETOL XR, TENCON, THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE, TIBSOVO, TRACLEER, TURALIO, VONJO, WELIREG, XCOPRI, XERMELO, XTANDI |
| Elacestrant/Strong and Moderate CYP3A4 Inhibitors SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Inhibitors of CYP3A4 may inhibit the metabolism of elacestrant.(1) CLINICAL EFFECTS: Concomitant use of a strong or moderate CYP3A4 inhibitor increases elacestrant plasma concentrations, which may increase the incidence and severity of adverse reactions.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of elacestrant states avoid concomitant use of strong or moderate CYP3A4 inhibitors with elacestrant.(1) The US manufacturer of elacestrant does not provide dose modification recommendations with strong and moderate CYP3A4 inhibitors. The Australian and UK manufacturers state concomitant use of strong or moderate CYP3A4 inhibitors should be avoided and an alternative concomitant medicinal product with no or minimal potential to inhibit CYP3A4 should be considered. If concomitant use of a strong CYP3A4 inhibitor is unavoidable, the elacestrant dose should be reduced to 172 mg once daily with careful monitoring of tolerability. Subsequent dose reduction to 86 mg once daily may be considered with moderate CYP3A4 inhibitors based on tolerability. If the CYP3A4 inhibitor is discontinued, the elacestrant dose should be increased to the dose used prior to the initiation of the CYP3A4 inhibitor (after 5 half-lives of the CYP3A4 inhibitor).(2,3) DISCUSSION: Coadministration of itraconazole (a strong CYP3A4 inhibitor) increased elacestrant area-under-curve (AUC) and maximum concentration (Cmax) by 5.3-fold and 4.4-fold, respectively.(1) Coadministration of fluconazole (a moderate CYP3A4 inhibitor) is predicted to increase elacestrant AUC and Cmax by 2.3-fold and 1.6-fold, respectively.(1) Strong inhibitors of CYP3A4 include: adagrasib, boceprevir, ceritinib, clarithromycin, cobicistat, ensitrelvir, idelalisib, indinavir, itraconazole, josamycin, ketoconazole, levoketoconazole, lonafarnib, lopinavir, mibefradil, mifepristone, nefazodone, nelfinavir, nirmatrelvir, paritaprevir, posaconazole, ribociclib, saquinavir, telaprevir, telithromycin, tipranavir, troleandomycin, tucatinib, and voriconazole.(4,5) Moderate CYP3A4 inhibitors include: amprenavir, aprepitant, atazanavir, avacopan, berotralstat, clofazimine, conivaptan, crizotinib, darunavir, diltiazem, dronedarone, duvelisib, erythromycin, fedratinib, fluconazole, fluvoxamine, fosamprenavir, fosnetupitant, imatinib, isavuconazonium, oral lefamulin, lenacapavir, letermovir, netupitant, nilotinib, nirogacestat, rilzabrutinib, schisandra, stiripentol, tofisopam, treosulfan, verapamil, and voxelotor.(4,5) |
AKYNZEO, APONVIE, APREPITANT, APTIVUS, ATAZANAVIR SULFATE, CARDIZEM, CARDIZEM CD, CARDIZEM LA, CARTIA XT, CAVHANZA, CINVANTI, CLARITHROMYCIN, CLARITHROMYCIN ER, CLOFAZIMINE, CONIVAPTAN-D5W, COPIKTRA, CRESEMBA, DANZITEN, DARUNAVIR, DIACOMIT, DIFLUCAN, DILT-XR, DILTIAZEM 12HR ER, DILTIAZEM 24HR ER, DILTIAZEM 24HR ER (CD), DILTIAZEM 24HR ER (LA), DILTIAZEM 24HR ER (XR), DILTIAZEM HCL, DILTIAZEM HCL-0.7% NACL, DILTIAZEM HCL-0.9% NACL, DILTIAZEM HCL-NACL, DILTIAZEM-D5W, E.E.S. 200, E.E.S. 400, EMEND, ERY-TAB, ERYPED 200, ERYPED 400, ERYTHROCIN LACTOBIONATE, ERYTHROCIN STEARATE, ERYTHROMYCIN, ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN LACTOBIONATE, EVOTAZ, FLUCONAZOLE, FLUCONAZOLE-NACL, FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE ER, FOSAMPRENAVIR CALCIUM, GENVOYA, GLEEVEC, GRAFAPEX, IMATINIB MESYLATE, IMKELDI, INREBIC, ITRACONAZOLE, ITRACONAZOLE MICRONIZED, KALETRA, KETOCONAZOLE, KISQALI, KORLYM, KRAZATI, LANSOPRAZOL-AMOXICIL-CLARITHRO, LOPINAVIR-RITONAVIR, MATZIM LA, MIFEPREX, MIFEPRISTONE, MULTAQ, NEFAZODONE HCL, NILOTINIB D-TARTRATE, NILOTINIB HCL, NOXAFIL, OGSIVEO, OMECLAMOX-PAK, ORLADEYO, PAXLOVID, POSACONAZOLE, PREVYMIS, PREZCOBIX, PREZISTA, RECORLEV, REYATAZ, SPORANOX, STRIBILD, SUNLENCA, SYMTUZA, TASIGNA, TAVNEOS, TIADYLT ER, TIAZAC, TOLSURA, TRANDOLAPRIL-VERAPAMIL ER, TUKYSA, VAPRISOL-5% DEXTROSE, VERAPAMIL ER, VERAPAMIL ER PM, VERAPAMIL HCL, VERAPAMIL SR, VFEND, VFEND IV, VIRACEPT, VOQUEZNA TRIPLE PAK, VORICONAZOLE, VORICONAZOLE (HPBCD), WAYRILZ, XALKORI, XENLETA, XOCOVA, YEZTUGO, ZOKINVY, ZYDELIG, ZYKADIA |
| Fluoroestradiol F-18/Estrogen Receptor Blockers (ERBs) SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Drugs that bind to the estrogen receptor (ER) may compete with the binding of radioactive diagnostic agent fluoroestradiol F-18.(1) CLINICAL EFFECTS: Concurrent use of estrogen receptor blockers such as selective estrogen receptor modulators (SERMs) and selective estrogen receptor down-regulators (SERDs) may reduce the detection of ER-positive lesions with fluoroestradiol F-18.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Before administering fluoroestradiol F-18, discontinue drugs that bind to the ER, such as SERMs and SERDs, for at least 5 biological half-lives.(1) The following washout periods apply when discontinuing ERBs, prior to fluoroestradiol F-18 administration: - Bazedoxifene = 7 days - Clomiphene = 25 days - Elacestrant = 11 days - Enclomiphene = 25 days - Fulvestrant = 28 weeks - Imlunestrant = 7 days - Ospemifene = 5 days - Raloxifene = 7 days - Tamoxifen = 8 weeks - Toremifene = 5 weeks DISCUSSION: The following ERBs are linked to this monograph: SERDs: elacestrant, imlunestrant, and fulvestrant. SERMs: bazedoxifene, clomiphene, enclomiphene, ospemifene, raloxifene, tamoxifen and toremifene. |
CERIANNA |
There are 0 severe interactions.
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Digoxin/P-glycoprotein (P-gp) Inhibitors SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: P-glycoprotein (P-gp) inhibitors may inhibit cellular efflux of digoxin at the levels of intestinal absorption, renal tubular secretion, and biliary-intestinal secretion.(1) CLINICAL EFFECTS: Concurrent administration of a P-gp inhibitor may result in elevated levels and toxicities of digoxin.(1) Symptoms of digoxin toxicity can include anorexia, nausea, vomiting, headache, fatigue, malaise, drowsiness, generalized muscle weakness, disorientation, hallucinations, visual disturbances, and arrhythmias. PREDISPOSING FACTORS: Low body weight, advanced age, impaired renal function, hypokalemia, hypercalcemia, and/or hypomagnesemia may increase the risk of digoxin toxicity. PATIENT MANAGEMENT: Monitor digoxin concentrations before initiating concomitant use with P-gp inhibitors and continue monitoring serum digoxin concentrations as recommended in the prescribing information for digoxin.(1) When digoxin levels are expected to be increased by over 50%, the manufacturer of digoxin recommends decreasing the dose of digoxin by approximately 30-50% or by modifying the dosing frequency to reduce digoxin concentrations.(1) When digoxin levels are expected to be increased by less than 50%, the manufacturer of digoxin recommends decreasing the dose of digoxin by approximately 15-30% or by modifying the dosing frequency to reduce digoxin concentrations.(1) DISCUSSION: Digoxin is a known substrate of P-gp. Inhibitors of P-gp may increase toxicity of digoxin.(1) In a clinical study, elacestrant increased the area-under-curve (AUC) and maximum concentration (Cmax) of digoxin by 1.1-fold and 1.3-fold, respectively.(2,3) In another clinical study, imlunestrant increased the area-under-curve (AUC) and maximum concentration (Cmax) of digoxin by 1.4-fold and 1.6-fold, respectively.(4) In another clinical study, maribavir increased the AUC and Cmax of digoxin by 1.2-fold and 1.25-fold, respectively.(5) Inhibitors of P-gp linked to this monograph include: abrocitinib, capmatinib, elacestrant, enzalutamide, imlunestrant, maribavir, selpercatinib, sparsentan, sotorasib, vepdegestrant, and vibegron.(2-7) |
DIGOXIN, DIGOXIN MICRONIZED, LANOXIN, LANOXIN PEDIATRIC |
The following contraindication information is available for ORSERDU (elacestrant hcl):
Drug contraindication overview.
*None.
*None.
There are 2 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Child-pugh class C hepatic impairment |
| Lactation |
There are 3 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Child-pugh class B hepatic impairment |
| Disease of liver |
| Pregnancy |
There are 2 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Hypercholesterolemia |
| Hypertriglyceridemia |
The following adverse reaction information is available for ORSERDU (elacestrant hcl):
Adverse reaction overview.
Adverse effects (including laboratory abnormalities) reported in >=10% of patients receiving elacestrant were musculoskeletal pain, nausea, vomiting, increased cholesterol, increased AST/ALT, increased triglycerides, fatigue, decreased hemoglobin, decreased sodium, increased creatinine, decreased appetite, diarrhea, headache, constipation, abdominal pain, hot flush, and dyspepsia.
Adverse effects (including laboratory abnormalities) reported in >=10% of patients receiving elacestrant were musculoskeletal pain, nausea, vomiting, increased cholesterol, increased AST/ALT, increased triglycerides, fatigue, decreased hemoglobin, decreased sodium, increased creatinine, decreased appetite, diarrhea, headache, constipation, abdominal pain, hot flush, and dyspepsia.
There are 2 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Increased alanine transaminase Increased aspartate transaminase |
None. |
| Rare/Very Rare |
|---|
| None. |
There are 21 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Acute abdominal pain Anemia Anorexia Constipation Diarrhea Drug-induced hot flash Dyspepsia Fatigue Headache disorder Hypercholesterolemia Hypertriglyceridemia Hyponatremia Musculoskeletal pain Nausea Vomiting |
Cough Dizziness Dyspnea Gastroesophageal reflux disease Insomnia Skin rash |
| Rare/Very Rare |
|---|
| None. |
The following precautions are available for ORSERDU (elacestrant hcl):
Safety and efficacy of elacestrant in pediatric patients have not been established.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Elacestrant use during pregnancy can cause fetal harm based on findings in an animal study and the mechanism of action of the drug. Human data on elacestrant use during pregnancy are not available to determine the drug-associated risk. Administration of oral elacestrant to pregnant rats during the period of organogenesis resulted in structural abnormalities and embryofetal death at maternal exposures below the recommended dose based on AUC.
Maternal toxicity (reduced weight gain, low food consumption, red vulvar discharge) was also observed in rats. Verify pregnancy status in females of reproductive potential prior to initiating elacestrant. Apprise patients of the potential hazard to the fetus if elacestrant is used during pregnancy.
Maternal toxicity (reduced weight gain, low food consumption, red vulvar discharge) was also observed in rats. Verify pregnancy status in females of reproductive potential prior to initiating elacestrant. Apprise patients of the potential hazard to the fetus if elacestrant is used during pregnancy.
It is unknown whether elacestrant distributes into human milk, or affects milk production or the breast-fed infant. Because of the potential for serious adverse reactions in breast-fed infants, advise women to not breast-feed during treatment with elacestrant and for 1 week after the last dose.
In the EMERALD trial, 43 and 17% of patients were >=65 and >=75 years of age. There were no overall differences in the safety or efficacy of elacestrant between patients >=65 years and younger adults. There was an insufficient number of patients >=75 years of age to assess age-related differences in safety or efficacy. No clinically important differences in elacestrant pharmacokinetics were observed based on age (range 24-89 years).
The following prioritized warning is available for ORSERDU (elacestrant hcl):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for ORSERDU (elacestrant hcl)'s list of indications:
| Er-positive, HEr2-negative, ESr1-mutated breast cancer | |
| C50.011 | Malignant neoplasm of nipple and areola, right female breast |
| C50.012 | Malignant neoplasm of nipple and areola, left female breast |
| C50.019 | Malignant neoplasm of nipple and areola, unspecified female breast |
| C50.021 | Malignant neoplasm of nipple and areola, right male breast |
| C50.022 | Malignant neoplasm of nipple and areola, left male breast |
| C50.029 | Malignant neoplasm of nipple and areola, unspecified male breast |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.121 | Malignant neoplasm of central portion of right male breast |
| C50.122 | Malignant neoplasm of central portion of left male breast |
| C50.129 | Malignant neoplasm of central portion of unspecified male breast |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast |
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast |
| C50.229 | Malignant neoplasm of upper-inner quadrant of unspecified male breast |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast |
| C50.329 | Malignant neoplasm of lower-inner quadrant of unspecified male breast |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast |
| C50.422 | Malignant neoplasm of upper-outer quadrant of left male breast |
| C50.429 | Malignant neoplasm of upper-outer quadrant of unspecified male breast |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast |
| C50.519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast |
| C50.521 | Malignant neoplasm of lower-outer quadrant of right male breast |
| C50.522 | Malignant neoplasm of lower-outer quadrant of left male breast |
| C50.529 | Malignant neoplasm of lower-outer quadrant of unspecified male breast |
| C50.611 | Malignant neoplasm of axillary tail of right female breast |
| C50.612 | Malignant neoplasm of axillary tail of left female breast |
| C50.619 | Malignant neoplasm of axillary tail of unspecified female breast |
| C50.621 | Malignant neoplasm of axillary tail of right male breast |
| C50.622 | Malignant neoplasm of axillary tail of left male breast |
| C50.629 | Malignant neoplasm of axillary tail of unspecified male breast |
| C50.811 | Malignant neoplasm of overlapping sites of right female breast |
| C50.812 | Malignant neoplasm of overlapping sites of left female breast |
| C50.819 | Malignant neoplasm of overlapping sites of unspecified female breast |
| C50.821 | Malignant neoplasm of overlapping sites of right male breast |
| C50.822 | Malignant neoplasm of overlapping sites of left male breast |
| C50.829 | Malignant neoplasm of overlapping sites of unspecified male breast |
| C50.911 | Malignant neoplasm of unspecified site of right female breast |
| C50.912 | Malignant neoplasm of unspecified site of left female breast |
| C50.919 | Malignant neoplasm of unspecified site of unspecified female breast |
| C50.921 | Malignant neoplasm of unspecified site of right male breast |
| C50.922 | Malignant neoplasm of unspecified site of left male breast |
| C50.929 | Malignant neoplasm of unspecified site of unspecified male breast |
Formulary Reference Tool